Vitae Pharmaceuticals is a clinical-stage company building a portfolio of first-/best-in-class compounds for diseases with significant unmet medical need.
- Chronic Kidney Disease - Lead compound VTP-27999, which completed Phase 1 clinical trials, is a novel, highly potent and selective direct renin inhibitor, with a potential best-in-class profile in the clinic.
- Alzheimer’s Disease and Diabetes - Partnered programs with Boehringer Ingelheim that have generated more than $130 million in upfront, research and milestone payments.
Atherosclerosis - identified compounds that modulate the Liver X Receptor (LXR) increasing reverse cholesterol transport and decreasing inflammation. This approach has the potential to offer atherosclerosis patients a novel alternative to current lipid lowering therapies.
Autoimmune Disease - RORγt program has the potential to inhibit the inflammatory Th17 response while leaving the rest of the immune system intact. This approach has been validated in the clinic using anti-IL17 antibodies.
- Rapidly advancing additional programs against new, attractive targets using its unique discovery approach.
Vitae Pharmaceuticals is led by a team of professionals that apply their extensive pharmaceutical industry experience to drive an entrepreneurial, highly focused enterprise. Vitae Pharmaceuticals has an internal staff of approximately 45 scientists representing diverse areas of expertise, complemented by a growing number of expert virtual team members and collaboration partners that extend the reach and capabilities of our own sophisticated in-house resources.
Vitae Pharmaceuticals is a leader in structure-based drug discovery (SBDD). All of our programs integrate the proprietary CONTOUR® SBDD platform with the experience and insights of a world-class R&D team.